Ann: Half Yearly Report and Accounts, page-111

As long as its not a market attack to give a T/over the best price from somewhere...seen it happen but whether the collision of circumstances could be used in this way...Hmmm don't know but the selling has been relentless and I watched Friday just get continued feed from sellers.
I was having a good ol think about positions and allocations within my portfolio and I know alot of water and shares have passed since the heady 300% lift in 1 day back in May2019. Showing the potential for volatility to work both ways. News would be timely/great but in this market sentiment would it even rate?
I do have a slight inkling that traders/daytraders just wanted out...holding parcels from those heady daze of May. Whether they would hold this long on the prospect the same pattern would replicate...don't know [any traders welcome to comment] then dump to liquidate funds for $ or elsewhere opportunities. If insto's/ sophisto's are just forced to go to cash after stumping up for the CR I would say the plan is flawed because a multi million dollar investment surely is a long view. I take some faith in this from the Co. Website:

SIGNIFICANT UPSIDE

Orthocell’s key products address markets worth more than US$10bn per annum and significant value upside potential exists for Orthocell, underpinned by its world leading diversified multiproduct portfolio of leading regenerative medicine products and recent M&A transactions executed in the sector.

DE-RISKED PRODUCT PORTFOLIO

Orthocell’s product portfolio is significantly de-risked and supported by substantial clinical data, publications in leading journals, regulatory approvals and significant partner interest from the world’s largest healthcare companies.

Implications with whats happening in China should not effect OCC directly, or am I missing some obscure connection there.
Was the Half yearly really that bad it triggered the "sell" button. We can see that revenue dropped yet we had new markets in Europe and a commitment from the December Cr that funds would go into and I quote:
Combined proceeds to be used to accelerate US, EU and AUS regulatory approvals and
commercialisation of CelGro®; advance the commercialisation of Ortho-ATI® and scale up
manufacturing facilities.
Now I know the timeline for the half yearly is dated till 31st Dec 2019. So a back up news release which address' the execution of the funded business plan would be a welcome note to existing holders and maybe a harbinger of the next Qtrs potential news flow. As manangement teams watching what unfolded this last week you would have to think as a strategy that getting some "good news stories" out there to reassure the market and identify that from your view going forward the market/virus machinations will have little or minimal effect on your companies operations. And if it does then lets not make it a secret...or id the "unknown" the biggest factor driving sellers. I for one don't see a problem with updates on a monthly basis re-funded business plans and their progress since the CR funds allocated.
OK bit of a rant but I am trying to keep a levelled approach and reviewing my investment decisions with some conviction, I guess like everyone else I'm a little rattled by the actual freefall but picking out stocks that overshot the market declines I needed to have an explanation of sorts. GLTAH.